Under the motto "Two Stories - One Future", Gerresheimer and Bormioli Pharma are presenting together at Pharmapack for the first time, after Gerresheimer’s successful completion of the Bormioli Pharma acquisition in December 2024. Pharmaceutical companies will benefit from an even wider range of containment solutions with suitable closure options and accessories, sustainable product lines and the combined innovative strength of both companies.
Special solutions for biologics
The focus of the trade show appearance will be on primary packaging solutions specially tailored to the requirements of sensitive biologics. With Gx Elite syringes, cartridges and vials, for example, Gerresheimer offers the highest quality and the best protection for injectable drugs. With EZ-fill Smart, Gerresheimer presents the next generation packaging platform for ready-to-fill (RTF) primary packaging such as vials and cartridges. Both the outstanding product quality of the Gx Elite Performance Level and the innovative new packaging platform are designed to provide the best possible protection for particularly sensitive and expensive drugs such as novel biologics and to enable efficient, smooth filling.
Trend towards therapy at home
With the Gx Inbeneo auto-injector and the Gx SensAir on-body drug delivery device, Gerresheimer is also addressing the trend towards home therapy. Both devices enable simple, patient-friendly application with high-precision dosing of the respective medication. The on-body drug delivery device can optionally be digitally connected and integrated into digital health platforms.
Sneak-Preview Gx Cap for adherence support in clinical trials
In the Innovation Gallery (F12), Gerresheimer will provide a first glimpse at an exciting new digital solution for adherence support in clinical trials. Sueyoung Yoon (Gerresheimer) will briefly present the solution on January 23 at 11:40 a.m. in the Innovation Gallery: Adherence to therapy is crucial to the success of clinical trials. If medication is not taken as intended, this could affect data integrity, trial efficiency and the safety of trial participants. Gx Cap for Clinical Trials is a digitally connected tablet container cap, which enables the monitoring of oral medication intake so that trial participants can be reminded to take their medication if necessary. Gx Cap is already being used successfully by pharmacies in the USA for remote therapeutic monitoring programs for certain therapeutic areas.
Gerresheimer conference highlights in the Learning Lab
Gerresheimer experts will be giving three presentations in the "Learning Lab" and "Sustainability Theater" at Pharmapack to provide insights and expertise to the interested public.
Reducing the Carbon Footprint of our Products - Renewable Energy and Material Innovation as Viable Solutions
January 22, 2025, 12:55 - 1:25 p.m.
Sustainability Theater K85
Speaker: Adrian Johnson (Gerresheimer)
A Partnership Worth More Than the Sum of Its Parts - Device Component Manufacturers Fulfil Syringe and System Performance Requirements
January 23, 2025, 10:10 - 10:40 a.m.
Learning Lab K3
Speakers: Sébastien Cordier (Aptar Pharma), Lucy Lee (SHL Medical), Bernd Zeiss (Gerresheimer)
The innovation journey: Developing EZ-fill Smart as the New Industry Standard for Ready-to-Use Vials
January 23, 2025, 2:30 - 3:00 p.m.
Learning Lab K3
Speaker: Holger Krenz (Gerresheimer)
Gerresheimer and Bormioli Pharma at Pharmapack Paris
Gerresheimer and Bormioli Pharma will be presenting their portfolio at Pharmapack in Paris on January 22 and 23, 2025 at booth F55.
Interested trade visitors can make an appointment with one of the experts here.
About Gerresheimer
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. The Group generated revenues of around €2bn in 2023 and currently employs around 13,400 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
Contact Gerresheimer
Jutta Lorberg
Head of Corporate Communication
T +49 211 6181 264
jutta.lorberg-remove@remove-gerresheimer.com
Marion Stolzenwald
Senior Manager Corporate Communication
T +49 1722424185
marion.stolzenwald-remove@remove-gerresheimer.com
